Other Events ·
Yale IRB approves patient recruitment for Parts B and C of Phase I/II trial for CMND-100
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. announced that Yale University’s Institutional Review Board has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, following positive safety results from Part A. The approval enables the company to accelerate enrollment at Yale School of Medicine’s Department of Psychiatry, joining other active sites including Johns Hopkins University and Israeli medical centers. Part A involved 24 participants across four ascending-dose cohorts who successfully completed treatment with no serious adverse events observed, reinforcing the compound's safety profile for treating Alcohol Use Disorder. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric and addiction disorders.